The Raise
Nervonik closed an oversubscribed $52.5 million Series B in April 2026, led by Amzak Health.
What They're Building
Nervonik is developing a next-generation, miniaturized, wireless neuromodulation platform for chronic neuropathic pain. The core innovation is a closed-loop system that reads nerve signals in real-time and adjusts stimulation.
Clinical Milestone
In June 2026, Nervonik announced successful completion of a first-in-human feasibility study demonstrating high-fidelity neural data recording from peripheral nerves in chronic pain patients.
Why This Matters
Closed-loop PNS represents a fundamentally different approach to chronic pain: instead of modulating the brain's interpretation, it addresses the nerve signal at its source.
